Skip to contentT
TELA Bio, Inc.
T
TELATELA Bio, Inc. Q3 2025 · 10-Q
Revenue$20.69M$20.69M+9.1% vs Q3 2024 Net Income-$8.60M-$8.60MN/M vs Q3 2024 EPS Diluted-$0.19-$0.19N/M vs Q3 2024 Gross Profit$13,969,000+8.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
TELA Bio, Inc. · CIK 1561921 · Engraved from SEC EDGAR
Operating Cash Flowderived-$5,719,000N/M Free Cash Flowderived-$5,930,000N/M Margins · derivedGross margin67.5%−0.3 pt vs Q3 2024
Operating margin-36.5%+12.9 pt vs Q3 2024
Net margin-41.6%+13.1 pt vs Q3 2024
ended Sep 30, 2025 · filed Nov 14, 2025 · 45 d after period end